Research programme: oxyntomodulin long-acting - OPKO Health

Drug Profile

Research programme: oxyntomodulin long-acting - OPKO Health

Alternative Names: Anti-obesity peptide - PROLOR Biotech; LA-Oxyntomodulin; Long-acting oxyntomodulin - PROLOR Biotech; MOD-1002; MOD-6030; MOD-630; OXY-CTP; OXY-RPEG

Latest Information Update: 09 Dec 2014

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator PROLOR Biotech
  • Developer OPKO Health
  • Class Anorectics; Antihyperglycaemics; Gastrointestinal hormones; Obesity therapies; Peptides
  • Mechanism of Action Glucagon like peptide 1 receptor agonists; Glucagon receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Obesity; Type 2 diabetes mellitus

Most Recent Events

  • 29 Aug 2013 PROLOR Biotech has been acquired by OPKO Health
  • 17 Apr 2012 Preclinical trials in Type-2 diabetes mellitus in Israel (unspecified route)
  • 17 Apr 2012 Pharmacodynamics data from preclinical studies in Obesity and Type-2 diabetes mellitus released by PROLOR Biotech
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top